Léonore Robieux

Dr. Léonore Robieux

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Patient Education and Counseling
Verified
Journal Article
Closed access
LRLéonore Robieux
Léonore Robieux
LKLucille Karsenti
Lucille Karsenti
MPMarc Pocard
Marc Pocard
CFCécile Flahault
Cécile Flahault

1 September 2017 in Psychiatry Research
Verified
Journal Article
Closed access
NMNils Myszkowski
Nils Myszkowski
EBEric Brunet-Gouet
Eric Brunet-Gouet
Paul RouxPaul Roux
Paul Roux
LRLéonore Robieux
Léonore Robieux
AMAntoine Malézieux
Antoine Malézieux
Franck ZenasniFranck Zenasni
Franck Zenasni

1 March 2018 in Psychologie Française
Verified
Journal Article
Closed access
LRLéonore Robieux
Léonore Robieux
Franck ZenasniFranck Zenasni
Franck Zenasni
CFC. Flahault
C. Flahault
JTJ.-L. Tavani
J.-L. Tavani

16 June 2017 in Familial Cancer
Verified
Journal Article
Open access
PDF file
ABAnne Bredart
Anne Bredart
JKJean-Luc Kop
Jean-Luc Kop
AAAntonis C. Antoniou
Antonis C. Antoniou
ACAlex P. Cunningham
Alex P. Cunningham
APAntoine De Pauw
Antoine De Pauw
RSRita Schmutlzer
Rita Schmutlzer
The ‘BOADICEA’ Web Application (BWA) used to assess breast cancer risk, is currently being further developed, to integrate additional genetic and non-genetic factors. We surveyed clinicians’ perceived acceptability of the existing BWA v3. An online survey was conducted through the BOADICEA website, and the British, Dutch, French and Swedish genetics societies. Cross-sectional data from 443 participants who provided at least 50% responses were analysed. Respondents varied in age and, clinical seniority, but mainly comprised women (77%) and genetics professionals (82%). Some expressed negative opinions about the scientific validity of BOADICEA (9%) and BWA v3 risk presentations (7–9%). Data entry time (62%), clinical utility (22%) and ease of communicating BWA v3 risks (13–17%) received additional negative appraisals. In multivariate analyses, controlling for gender and country, data entry time was perceived as longer by genetic counsellors than clinical geneticists (p < 0.05). Respondents who (1) considered hormonal BC risk factors as more important (p < 0.01), and (2) communicated numerical risk estimates more frequently (p < 0.001), judged BWA v3 of lower clinical utility. Respondents who carried out less frequent clinical activity (p < 0.01) and respondents with ‘11 to 15 years’ seniority (p < 0.01) had less favourable opinions of BWA v3 risk presentations. Seniority of ‘6 to 10 years’ (p < 0.05) and more frequent numerical risk communication (p < 0.05) were associated with higher fear of communicating the BWA v3 risks to patients. The level of genetics training did not affect opinions. Further development of BWA should consider technological, genetics service delivery and training initiatives.

4 November 2024 in Psychology, Health & Medicine
Verified
Journal Article
Closed access
SZSylvia Zimmers
Sylvia Zimmers
LRLéonore Robieux
Léonore Robieux
CBCatherine Bungener
Catherine Bungener
In Parkinson's disease (PD), a large number of individuals are confronted with pain. This issue has been receiving increasing attention in literature in recent years, as the complexity of pain in this disease makes its evaluation and treatment challenging. However, psychological variables related to the pain experience have received limited attention, especially when it comes to the exploration of beliefs regarding pain which, to our knowledge, remains unexplored in PD. Pain beliefs are defined as a subset of a patient's belief system which represents a personal understanding of the pain experience. Four dimensions of pain beliefs have been isolated in literature: mystery, pain permanence, pain constancy and self-blame. Thus, the goal of this study was first to describe pain beliefs in individuals with PD and second, to explore the relationships between pain beliefs and clinical and psychological variables. One hundred and sixty-nine international individuals with PD completed an online survey with socio-demographic and medical data. Participants completed self-report instruments to assess their pain (King's Parkinson's Disease Pain Questionnaire, McGill Pain Questionnaire and Brief Pain Inventory), psychological distress (Beck Depression Inventory, short-form and Parkinson Anxiety Scale), pain catastrophizing (Pain Catastrophizing Scale) and pain beliefs catastrophizing (Pain Beliefs and Perception Inventory). The study's findings revealed that most participants' beliefs are marked by the dimension of permanence, suggesting that individuals with PD perceive the pain experience as chronic and enduring. Meanwhile, pain is minimally perceived as constant, mysterious, or a source of guilt. Our finding concerning the permanence dimension deserves specific attention: even though this belief is prevalent in our population, it is not, or only weakly, associated with an impact on mood or pain catastrophizing. These results bring forth several hypotheses for understanding, highlighting the role of acceptance, and offer new perspectives toward improving clinical practices in terms of assessing and managing pain in PD.

17 July 2023 in The Journal of Creative Behavior
Verified
Journal Article
Closed access
MBMarion Botella
Marion Botella
LRLéonore Robieux
Léonore Robieux
BFBenjamin Frantz
Benjamin Frantz